Luckily, I was able to see Professor Ivan Goldberg in Sydney, where I have had surgery on my left eye and treatment with drops, and many thorough check-ups and tests on both eyes.
Thursday the 16th of May 2024, marks Global Accessibility Awareness Day, a key date in our calendar to get everyone talking, thinking, and learning about digital access and inclusion.
A couple of years later I developed traumatic glaucoma as a direct result of the surgery, and have received various treatments since, taking care of both eyes as a precaution.
During the past decade, glaucoma care in the UK has changed dramatically, with more non-medical ophthalmic practitioners involved. As such, optometrists and other non-medical professionals have been delivering laser treatments including SLT in the Hospital Eye Service (HES).
Funding research to enhance glaucoma detection, treatment, and the lives of individuals with glaucoma is fundamental to Glaucoma Australia's mission to prevent glaucoma blindness.
Researchers have identified a potentially transformative factor for regenerating damaged optic nerves, which they believe could one day prevent irreversible blindness.
The landmark Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial – that ultimately recommended selective laser trabeculoplasty (SLT) as a first-line glaucoma intervention – has published six-year results further demonstrating the clinical effectiveness of the treatment.
As issues with compliance and a reduction of life-quality are commonly associated with eye drops, the industry is exploring new avenues that are revolutionising the treatment landscape.
With the rising numbers of patients diagnosed with glaucoma – and oversubscription of public ophthalmology departments – the Glaucoma Community Collaborative Care Program at the Royal Victorian Eye and Ear Hospital in Melbourne is designed to alleviate some of this pressure.